ArticleTranslational lung cancer research2022

A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.

Yue Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.